New York State Medicaid Program Ordered Ambulatory Procedure Codes

Total Page:16

File Type:pdf, Size:1020Kb

New York State Medicaid Program Ordered Ambulatory Procedure Codes NEW YORK STATE MEDICAID PROGRAM ORDERED AMBULATORY PROCEDURE CODES Ordered Ambulatory Procedure Codes Table of Contents GENERAL INFORMATION ............................................................................................................. 6 LABORATORY SERVICES INFORMATION .................................................................................... 6 RADIOLOGY INFORMATION ......................................................................................................... 6 MMIS MODIFIERS ........................................................................................................................ 10 RADIOLOGY SERVICES .............................................................................................................. 11 DIAGNOSTIC RADIOLOGY (DIAGNOSTIC IMAGING)............................................................... 11 HEAD AND NECK.................................................................................................................. 11 CHEST .................................................................................................................................. 12 SPINE AND PELVIS .............................................................................................................. 13 UPPER EXTREMITIES .......................................................................................................... 14 LOWER EXTREMITIES ......................................................................................................... 15 ABDOMEN ............................................................................................................................ 16 GASTROINTESTINAL TRACT ............................................................................................... 17 URINARY TRACT .................................................................................................................. 18 GYNECOLOGICAL AND OBSTETRICAL ............................................................................... 18 HEART .................................................................................................................................. 18 VASCULAR PROCEDURES .................................................................................................. 19 MISCELLANEOUS PROCEDURES ........................................................................................ 20 DIAGNOSTIC ULTRASOUND ................................................................................................... 21 HEAD AND NECK.................................................................................................................. 21 CHEST .................................................................................................................................. 21 ABDOMEN AND RETROPERITONEUM ................................................................................. 21 SPINAL CANAL ..................................................................................................................... 21 PELVIS .................................................................................................................................. 22 GENITALIA ............................................................................................................................ 24 EXTREMITIES ....................................................................................................................... 24 VASCULAR STUDIES............................................................................................................ 24 ULTRASONIC GUIDANCE PROCEDURES ............................................................................ 24 MISCELLANEOUS ULTRASONIC PROCEDURE ................................................................... 24 RADIOLOGIC GUIDANCE ......................................................................................................... 26 FLUOROSCOPIC GUIDANCE ............................................................................................... 26 Version 2021-2 Page 2 of 73 Ordered Ambulatory Procedure Codes COMPUTED TOMOGRAPHY GUIDANCE .............................................................................. 26 MAGNETIC RESONANCE GUIDANCE .................................................................................. 26 BREAST, MAMMOGRAPHY ...................................................................................................... 26 BONE/JOINT STUDIES ............................................................................................................. 27 RADIATION ONCOLOGY .......................................................................................................... 28 CLINICAL TREATMENT PLANNING (EXTERNAL AND INTERNAL SOURCES) ..................... 28 MEDICAL RADIATION PHYSICS, DOSIMETRY, TREATMENT DEVICES AND SPECIAL SERVICES ............................................................................................................................ 28 MISCELLANEOUS PROCEDURES ........................................................................................ 29 RADIATION TREATMENT DELIVERY.................................................................................... 30 RADIATION TREATMENT MANAGEMENT ............................................................................ 30 PROTON BEAM TREATMENT DELIVERY ............................................................................. 31 HYPERTHERMIA................................................................................................................... 31 CLINICAL INTRACAVITARY HYPERTHERMIA ...................................................................... 31 CLINICAL BRACHYTHERAPY ............................................................................................... 31 NUCLEAR MEDICINE ............................................................................................................... 32 THERAPEUTIC...................................................................................................................... 37 POSITRON EMISSION TOMOGRAPHY (PET) .......................................................................... 40 MEDICINE SERVICES.................................................................................................................. 41 IMMUNIZATIONS ...................................................................................................................... 41 MISCELLANEOUS DRUGS AND SOLUTIONS .......................................................................... 45 HYDRATION, THERAPEUTIC, PROPHYLACTIC, DIAGNOSTIC INJECTIONS and INFUSIONS, and CHEMOTHERAPY and OTHER HIGHLY COMPLEX DRUG or HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION ....................................................................................................... 51 HYDRATION.......................................................................................................................... 51 THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC INJECTIONS AND INFUSIONS (EXCLUDES CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION) ................................................................ 51 CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION .................................................................................. 52 CHEMOTHERAPY DRUGS ....................................................................................................... 53 GASTROENTEROLOGY ........................................................................................................... 56 OPHTHALMOLOGY .................................................................................................................. 57 GENERAL OPHTHALMOLOGICAL SERVICES ...................................................................... 57 SPECIAL OPHTHALMOLOGICAL SERVICES ........................................................................ 57 Version 2021-2 Page 3 of 73 Ordered Ambulatory Procedure Codes OPHTHALMOSCOPY ............................................................................................................ 58 MISCELLANEOUS SPECIALIZED SERVICES ....................................................................... 58 OTORHINOLARYNGOLOGIC & VESTIBULAR SERVICES ........................................................ 59 AUDIOLOGIC FUNCTION TESTS WITH MEDICAL DIAGNOSTIC EVALUATION.................... 59 CARDIOVASCULAR ................................................................................................................. 60 CARDIOGRAPHY .................................................................................................................. 60 CARDIOVASCULAR DEVICE MONITORING-IMPLANTABLE AND WEARABLE DEVICES ..... 61 ECHOCARDIOGRAPHY ........................................................................................................ 62 MISCELLANEOUS VASCULAR STUDIES .............................................................................. 63 NON INVASIVE VASCULAR DIAGNOSTIC STUDIES ................................................................ 63 CEREBROVASCULAR ARTERIAL STUDIES ......................................................................... 64 EXTREMITY ARTERIAL STUDIES (INCLUDING DIGITS) ....................................................... 64 EXTREMITY VENOUS STUDIES (INCLUDING DIGITS) ......................................................... 65 VISCERAL AND PENILE VASCULAR STUDIES ....................................................................
Recommended publications
  • Focal Spot, Spring 2006
    Washington University School of Medicine Digital Commons@Becker Focal Spot Archives Focal Spot Spring 2006 Focal Spot, Spring 2006 Follow this and additional works at: http://digitalcommons.wustl.edu/focal_spot_archives Recommended Citation Focal Spot, Spring 2006, April 2006. Bernard Becker Medical Library Archives. Washington University School of Medicine. This Book is brought to you for free and open access by the Focal Spot at Digital Commons@Becker. It has been accepted for inclusion in Focal Spot Archives by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. SPRING 2006 VOLUME 37, NUMBER 1 *eiN* i*^ MALLINCKRC RADIOLO AJIVERSITY *\ irtual Colonoscopy: a Lifesaving Technology ^.IIMi.|j|IUII'jd-H..l.i.|i|.llJ.lii|.|.M.; 3 2201 20C n « ■ m "■ ■ r. -1 -1 NTENTS FOCAL SPOT SPRING 2006 VOLUME 37, NUMBER 1 MIR: 75 YEARS OF RADIOLOGY EXPERIENCE In the early 1900s, radiology was considered by most medical practitioners as nothing more than photography. In this 75th year of Mallinckrodt Institute's existence, the first of a three-part series of articles will chronicle the rapid advancement of radiol- ogy at Washington University and the emergence of MIR as a world leader in the field of radiology. THE METABOLISM OF THE DIABETIC HEART More diabetic patients die from cardiovascular disease than from any other cause. Researchers in the Institute's Cardiovascular Imaging Laboratory are finding that the heart's metabolism may be one of the primary mechanisms by which diseases such as diabetes have a detrimental effect on heart function. VIRTUAL C0L0N0SC0PY: A LIFESAVING TECHNOLOGY More than 55,000 Americans die each year from cancers of the colon and rectum.
    [Show full text]
  • Resting Coronary Flow Velocity in The
    European Heart Journal – Cardiovascular Imaging (2012) 13,79–85 CLINICAL/ORIGINAL PAPERS doi:10.1093/ehjci/jer153 Resting coronary flow velocity in the functional evaluation of coronary artery stenosis: study on sequential use of computed tomography angiography and transthoracic Doppler Downloaded from https://academic.oup.com/ehjcimaging/article/13/1/79/2397059 by guest on 30 September 2021 echocardiography Esa Joutsiniemi 1, Antti Saraste 1,2*, Mikko Pietila¨ 1, Heikki Ukkonen 1,2, Sami Kajander 2, Maija Ma¨ki 2,3, Juha Koskenvuo 3, Juhani Airaksinen 1, Jaakko Hartiala 3, Markku Saraste 3, and Juhani Knuuti 2 1Department of Cardiology, Turku University Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland; 2Turku PET Centre, Kiinamyllynkatu 4-8, 20520 Turku, Finland; and 3Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland Received 10 March 2011; accepted after revision 2 August 2011; online publish-ahead-of-print 30 August 2011 Aims Accelerated flow at the site of flow-limiting stenosis can be detected by transthoracic Doppler echocardiography (TTDE). We studied feasibility and accuracy of sequential coronary computed tomography angiography (CTA) and TTDE in detection of haemodynamically significant coronary artery disease (CAD). ..................................................................................................................................................................................... Methods We prospectively enrolled 107 patients with intermediate (30–70%) pre-test likelihood of CAD. All patients under- and results went CTA using a 64-slice scanner. Using TTDE, the ratio of maximal diastolic flow velocity to pre-stenotic flow velocity (M/P ratio) was measured in the coronary segments with stenosis in CTA. In all patients, the results were compared with invasive coronary angiography, including measurement of fractional flow reserve when appropriate.
    [Show full text]
  • Fluorescein Angiography Findings in Both Eyes of a Unilateral Retinoblastoma Case During Intra-Arterial Chemotherapy with Melphalan
    Int J Ophthalmol, Vol. 12, No. 12, Dec.18, 2019 www.ijo.cn Tel: 8629-82245172 8629-82210956 Email: [email protected] ·Letter to the Editor· Fluorescein angiography findings in both eyes of a unilateral retinoblastoma case during intra-arterial chemotherapy with melphalan Cem Ozgonul1, Neeraj Chaudhary2, Raymond Hutchinson3, Steven M. Archer1, Hakan Demirci1 1Department of Ophthalmology and Visual Sciences, W.K. was inserted into the left femoral artery, advanced into the Kellogg Eye Center, MI 48105, USA internal carotid and up to the origin of the ophthalmic artery. 2Department of Radiology, University of Michigan, MI 48109, Once the catheter tip position was confirmed at the origin USA of the ophthalmic artery by fluoroscopy, 5 mg melphalan 3Department of Pediatric Hematology/Oncology, University of was infused in a pulsatile fashion over 30min. There was Michigan, MI 48109, USA no anatomical variant of orbital vascular structure. During Correspondence to: Hakan Demirci. Department of the 2nd IAC, following the infusion of melphalan, sodium Ophthalmology and Visual Science, W.K. Kellogg Eye Center, fluorescein dye at a dose of 7.7 mg/kg was injected through the 1000 Wall St, Ann Arbor, MI 48105, USA. hdemirci@med. same microcatheter. Real-time FA was recorded by using the umich.edu RetCam III (Clarity Medical Systems, Pleasanton, California). Received: 2018-11-01 Accepted: 2019-04-09 FA was repeated 4wk later during the 3rd IAC in the same manner, before infusion of the chemotherapy. In both sessions, DOI:10.18240/ijo.2019.12.24 there was no catheterization or injection of contrast material into the untreated carotid and ophthalmic artery.
    [Show full text]
  • Anorectal Disorders Satish S
    Gastroenterology 2016;150:1430–1442 Anorectal Disorders Satish S. C. Rao,1 Adil E. Bharucha,2 Giuseppe Chiarioni,3,4 Richelle Felt-Bersma,5 Charles Knowles,6 Allison Malcolm,7 and Arnold Wald8 1Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia; 2Department of Gastroenterology and Hepatology, Mayo College of Medicine, Rochester, Minnesota; 3Division of Gastroenterology of the University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; 4Division of Gastroenterology and Hepatology and UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 5Department of Gastroenterology/Hepatology, VU Medical Center, Amsterdam, The Netherlands; 6National Centre for Bowel Research and Surgical Innovation, Blizard Institute, Queen Mary University of London, London, United Kingdom; 7Division of Gastroenterology, Royal North Shore Hospital, and University of Sydney, Sydney, Australia; 8Division of Gastroenterology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin This report defines criteria and reviews the epidemiology, questionnaires and bowel diaries are correlated,5 some pathophysiology, and management of the following com- patients may not accurately recall bowel symptoms6; hence, mon anorectal disorders: fecal incontinence (FI), func- symptom diaries may be more reliable. tional anorectal pain, and functional defecation disorders. In this report, we examine the prevalence and patho- FI is defined as the recurrent uncontrolled passage of fecal physiology of anorectal disorders, listed in Table 1,and material for at least 3 months. The clinical features of FI provide recommendations for diagnostic evaluation and are useful for guiding diagnostic testing and therapy. management. These supplement practice guidelines rec- ANORECTAL Anorectal manometry and imaging are useful for evalu- ommended by the American Gastroenterological Associa- fl ating anal and pelvic oor structure and function.
    [Show full text]
  • Research Article Magnetic Resonance Sialography Findings of Submandibular Ducts Imaging
    Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 417052, 6 pages http://dx.doi.org/10.1155/2013/417052 Research Article Magnetic Resonance Sialography Findings of Submandibular Ducts Imaging Nezahat Karaca ErdoLan,1 Canan Altay,2 Nesibe Özenler,3 TuLba Bozkurt,1 Engin Uluç,1 Berna Dirim Mete,1 and Esmail Özdemir4 1 Department of Radiology, Izmir Ataturk¨ Research and Training Hospital, Basın Sitesi, Karabaglar,˘ 35360 Izmir, Turkey 2 Department of Radiology, Medical School, Dokuz Eylul University, Inciralti, 35340 Izmir, Turkey 3 Department of Radiology, Balıkesir Ataturk¨ State Hospital, Yıldız Mahallesi Soma Caddesi No. 1, 10100 Balıkesir, Turkey 4 Universal Ege Health Hospital, 35220 Izmir, Turkey Correspondence should be addressed to Canan Altay; [email protected] Received 2 April 2013; Revised 29 May 2013; Accepted 12 June 2013 Academic Editor: Yoshito Tsushima Copyright © 2013 Nezahat Karaca Erdogan˘ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. We aimed to assess the problem solving capability of magnetic resonance sialography (MR sialography), a noninvasive method for imaging submandibular gland ducts and determining duct-related pathologies, by comparing diseased and healthy cases. Materials and Methods. We conducted radiological assessment on a total of 60 submandibular glands (mean age 44.7) in 20 cases and 10 volunteers. MR sialography examinations were conducted with single-shot fast spin-echo sequence by using a surface coil placed on the submandibular gland. Each gland was evaluated in terms of the length, width and stricture of the main duct, as well as the difference between the intraparenchymal duct width, and the main duct width.
    [Show full text]
  • Risk Factors for Adverse Reactions of Fundus Fluorescein Angiography
    Original Article Risk factors for adverse reactions of fundus fluorescein angiography Yi Yang1, Jingzhuang Mai2, Jun Wang1 1Department of Ophthalmology, 2Epidemiology Division, Department of Cardiac Surgery, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangzhou 510080, China Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: Y Yang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: Y Yang, JZ Mai; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Yi Yang. Department of Ophthalmology, Guangdong General Hospital, #106, Zhongshan Second Road, Guangzhou 510080, China. Email: [email protected]. Background: To explore the difference between the outcomes of correlations between a series of variables and adverse reactions (ARs) to fluorescein from univariate and multivariate analysis and to evaluate the nausea effects in different age groups. Methods: A retrospective study of patients undergoing consecutive fluorescein angiography between March 2010 and February 2012 was conducted. No patients were excluded on the ground of age, presence of atopy, allergy history, previous procedures without severe allergic ARs, asymptomatic hypertension and kidney failure with serum creatinine levels lower than 250 μmol/L or with renal dialysis. Results: A total of 829 patients were enrolled and 22.2% of them had ARs. The majority of reactions were nausea (12.1%) which occurred less when age became old (P<0.0001). When the correlations between a series of variables and ARs were assessed separately, age (P<0.0001), prior reactions (P<0.0001) and motion sickness (P=0.0062) were highly and cardio/cerebrovascular disease (P=0.0015), diabetes (P=0.0001) and renal disease (P=0.0219) were lowly related to ARs.
    [Show full text]
  • Smartphone-Based Dilated Fundus Photography and Near Visual Acuity Testing As Inexpensive Screening Tools to Detect Referral Warranted Diabetic Eye Disease
    Smartphone-Based Dilated Fundus Photography and Near Visual Acuity Testing as Inexpensive Screening Tools to Detect Referral Warranted Diabetic Eye Disease BRIAN C. TOY, MD,*† DAVID J. MYUNG, MD, PHD,*† LINGMIN HE, MD,*† CAROLYN K. PAN, MD,*† ROBERT T. CHANG, MD,* ALISON POLKINHORNE, MA,‡ DOUGLAS MERRELL, BS,‡ DOUG FOSTER, MBA,‡ MARK S. BLUMENKRANZ, MD* Purpose: To compare clinical assessment of diabetic eye disease by standard dilated examination with data gathered using a smartphone-based store-and-forward teleoph- thalmology platform. Methods: 100 eyes of 50 adult patients with diabetes from a health care safety-net ophthalmology clinic. All patients underwent comprehensive ophthalmic examination. Concurrently, a smartphone was used to estimate near visual acuity and capture anterior and dilated posterior segment photographs, which underwent masked, standardized review. Quantitative comparison of clinic and smartphone-based data using descriptive, kappa, Bland-Altman, and receiver operating characteristic analyses was performed. Results: Smartphone visual acuity was successfully measured in all eyes. Anterior and posterior segment photography was of sufficient quality to grade in 96 and 98 eyes, respectively. There was good correlation between clinical Snellen and smartphone visual acuity measurements (rho = 0.91). Smartphone-acquired fundus photographs demon- strated 91% sensitivity and 99% specificity to detect moderate nonproliferative and worse diabetic retinopathy, with good agreement between clinic and photograph grades (kappa = 0.91 ± 0.1, P , 0.001; AUROC = 0.97, 95% confidence interval, 0.93–1). Conclusion: The authors report a smartphone-based telemedicine system that demon- strated sensitivity and specificity to detect referral-warranted diabetic eye disease as a proof-of-concept. Additional studies are warranted to evaluate this approach to expanding screening for diabetic retinopathy.
    [Show full text]
  • Clinical Review Karen Bleich NDA 020351 Supplement 44 (CCTA) Visipaque (Iodixanol)
    Clinical Review Karen Bleich NDA 020351 Supplement 44 (CCTA) Visipaque (iodixanol) CLINICAL REVIEW Application Type Supplemental New Drug Application Application Number(s) NDA 020351 s44 Priority or Standard Priority Submit Date(s) October 6th, 2016 Received Date(s) October 18th, 2016 PDUFA Goal Date April 5th, 2017 Division/Office Division of Medical Imaging Products/Office of Drug Evaluation IV Reviewer Name(s) Karen Bleich, MD Review Completion Date March 10th, 2017 Established Name Iodixanol (Proposed) Trade Name Visipaque Injection Applicant GE Healthcare Formulation(s) 320 mgI/mL Dosing Regimen 70-80 mL main bolus volume (does not include optional test bolus volume of 20 mL) at a flow rate of(b) (4) mL/s, followed by 20 mL saline flush Applicant Proposed For use in coronary computed tomography angiography (CCTA) to Indication(s)/Population(s) assist in the diagnostic evaluation of patients with suspected coronary artery disease. Recommendation on Approval Regulatory Action Recommended For use in coronary computed tomography angiography (CCTA) to Indication(s)/Population(s) assist in the diagnostic evaluation of patients with suspected (if applicable) coronary artery disease. CDER Clinical Review Template 2015 Edition 1 Reference ID: 4068412 Clinical Review Karen Bleich NDA 020351 Supplement 44 (CCTA) Visipaque (iodixanol) Table of Contents Glossary ........................................................................................................................................... 8 1 Executive Summary ..............................................................................................................
    [Show full text]
  • Imaging in Double Gall Bladder with Acute Cholecystitis—A Rare Entity
    Surgical Science, 2014, 5, 273-279 Published Online July 2014 in SciRes. http://www.scirp.org/journal/ss http://dx.doi.org/10.4236/ss.2014.57047 Imaging in Double Gall Bladder with Acute Cholecystitis—A Rare Entity Praveen Kumar Vasanthraj, Rajoo Ramachandran, Kumaresh Athiyappan, Anupama Chandrasekharan, Cunnigaiper Dhanasekaran Narayanan Department of Radiology, Sri Ramachandra University, Chennai, India Email: [email protected] Received 28 April 2014; revised 26 May 2014; accepted 22 June 2014 Copyright © 2014 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Duplication of gall bladder is a rare congenital anomaly of the hepatobiliary system. It is a very important entity in clinical practice as preoperative diagnosis plays a significant role in the man- agement and to avoid unnecessary bile duct injury during surgery. We report a case of duplicated gall bladder presenting as acute cholecystitis. Keywords Gall Bladder, Duplication, Cholecystitis 1. Introduction Gall bladder (GB) duplication is a rare congenital anomaly of hepatobiliary system with a reported incidence of about 1 per 4000 autopsies [1]. Duplication of gall bladder and their varying anatomical positions are associated with an increased risk of complications including biliary leak after laparoscopic or open cholecystectomy [2]-[5]. 2. Case Presentation A 45 years old lady presented with complaints of abdomen pain for the past two days. It was colicky type pain, intermittent in nature and localized to the right hypochondrium. She also gave history of three episodes of vo- miting which was non bilious, non blood stained and non foul smelling.
    [Show full text]
  • The Challenge of Assessing Heart Valve Prostheses by Doppler Echocardiography
    Editorial Comment The Challenge of Assessing Heart Valve Prostheses by Doppler Echocardiography Helmut Baumgartner, MD, Muenster, Germany The assessment of prosthetic valve function remains challenging. by continuous-wave Doppler measurement. Using these velocities Echocardiography has become the key diagnostic tool not only be- for the calculation of transvalvular gradients results in marked overes- cause of its noninvasive nature and wide availability but also because timation of the actual pressure drop across the prostheses.6 The fact of limitations inherent in alternative diagnostic techniques. Invasive that this phenomenon more or less disappears in malfunctioning bi- evaluation is limited particularly in mechanical valves that cannot leaflet prostheses when the funnel-shaped central flow channel ceases be crossed with a catheter, and in patients with both aortic and mitral to exist because of restricted leaflet motion makes the interpretation valve replacements, full hemodynamic assessment would even of Doppler data and their use for accurate detection of prosthesis mal- require left ventricular puncture. Although fluoroscopy and more function even more complicated.7 Furthermore, the lack of a flat ve- recently computed tomography allow the visualization of mechanical locity profile and the central high velocities described above cause valves and the motion of their occluders, the evaluation of prosthetic erroneous calculations of valve areas when the continuity equation valves typically relies on Doppler echocardiography. incorporates such measurements.8 For these reasons, the analysis of Although Doppler echocardiography has become an ideal nonin- occluder motion using fluoroscopy (in mitral prostheses, this may vasive technique for the evaluation of native heart valves and their also be obtained on transesophageal echocardiography) remains es- function, the assessment of prosthetic valves has remained more dif- sential to avoid the misinterpretation of high Doppler velocities across ficult.
    [Show full text]
  • Reoperative Techniques and Management in Hirschsprung Disease: a Narrative Review
    14 Review Article Reoperative techniques and management in Hirschsprung disease: a narrative review Farokh R. Demehri^, Belinda H. Dickie Department of Surgery, Boston Children’s Hospital, Boston, MA, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors Correspondence to: Farokh R. Demehri, MD. Department of Surgery, Boston Children’s Hospital, 300 Longwood Ave, Fegan 3, Boston, MA 02115, USA. Email: [email protected]. Abstract: The majority of children who undergo operative management for Hirschsprung disease have favorable results. A subset of patients, however, have long-term dysfunctional stooling, characterized by either frequent soiling or obstructive symptoms. The evaluation and management of a child with poor function after pull-through for Hirschsprung disease should be conducted by an experienced multidisciplinary team. A systematic workup is focused on detecting pathologic and anatomic causes of pull- through dysfunction. This includes an exam under anesthesia, pathologic confirmation including a repeat biopsy, and a contrast enema, with additional studies depending on the suspected etiology. Obstructive symptoms may be due to technique-specific types of mechanical obstruction, histopathologic obstruction, or dysmotility—each of which may benefit from reoperative surgery. The causes of soiling symptoms include loss of the dentate line and damage to the anal sphincter, which generally do not benefit from revision of the pull-through, and pseudo-incontinence, which may reveal underlying obstruction. A thorough understanding of the types of complications associated with various pull-through techniques aids in the evaluation of a child with postoperative dysfunction.
    [Show full text]
  • ICD~10~PCS Complete Code Set Procedural Coding System Sample
    ICD~10~PCS Complete Code Set Procedural Coding System Sample Table.of.Contents Preface....................................................................................00 Mouth and Throat ............................................................................. 00 Introducton...........................................................................00 Gastrointestinal System .................................................................. 00 Hepatobiliary System and Pancreas ........................................... 00 What is ICD-10-PCS? ........................................................................ 00 Endocrine System ............................................................................. 00 ICD-10-PCS Code Structure ........................................................... 00 Skin and Breast .................................................................................. 00 ICD-10-PCS Design ........................................................................... 00 Subcutaneous Tissue and Fascia ................................................. 00 ICD-10-PCS Additional Characteristics ...................................... 00 Muscles ................................................................................................. 00 ICD-10-PCS Applications ................................................................ 00 Tendons ................................................................................................ 00 Understandng.Root.Operatons..........................................00
    [Show full text]